| Literature DB >> 26673878 |
Ketaki R Desai1, Dhrupadsinh K Rajput1, Pragnesh B Patel1, Hyacinth N Highland1.
Abstract
India is one of the endemic areas where control of malaria has become a formidable task. Artesunate is the current antimalarial drug used to treat malaria, especially chloroquine resistant. The objective of the present study was to investigate the dose-dependent effect of oral administration of artesunate on the oxidative parameters in testes of adult male Swiss albino mice and ameliorative efficacy of curcumin, a widely used antioxidant. An oral dose of 150 mg/kg body weight (bwt; low dose) and 300 mg/kg bwt (high dose) of artesunate was administered for a period of 45 days to male mice, and ameliorative efficacy of curcumin was also assessed. The results revealed that artesunate caused significant alteration in oxidative parameters in dose-dependent manner. Administration of artesunate brought about significant decrease in activities of superoxide dismutase, glutathione, glutathione peroxidase, and glutathione reductase, whereas lipid peroxidation and glutathione-S-transferase activity were found to be significantly increased. The results obtained show that oxidative insult is incurred upon the intracellular antioxidant system of testis tissue by artesunate treatment. Further, administration of curcumin at the dose level of 80 mg/kg bwt along with both doses of artesunate attenuated adverse effects in male mice.Entities:
Keywords: antimalarial drug; antioxidant; artesunate; curcumin; testis
Year: 2015 PMID: 26673878 PMCID: PMC4674183 DOI: 10.1177/1559325815592393
Source DB: PubMed Journal: Dose Response ISSN: 1559-3258 Impact factor: 2.658
Alteration in LPO (TBARS) and SOD Content in Testis of Control and Treated Animals.
| Groups | LPO (nanomoles of MDA/mg tw/ 60 min) | SOD (units of SOD/mg protein) | |||
|---|---|---|---|---|---|
| Control (A) | 62.5 ± 1.62 | 0.35 ± 0.02 | |||
| Artesunate (150 mg/kg bwt) (B) | 73.3 ± 2.85b | 0.28 ± 0.03b | |||
| Artesunate (300 mg/kg bwt) (C) | 76.6 ± 2.38c | 0.25 ± 0.03c | |||
| Curcumin (80 mg/kg bwt) (D) | 61.1 ± 2.50 NS | 0.37 ± 0.01 NS | |||
| Artesunate (150 mg/kg bwt) + Curcumin (80 mg/kg bwt) (E) | 62.9 ± 3.10 NS | 0.33 ± 0.03 NS | |||
| Artesunate (300 mg/kg bwt) + Curcumin (80 mg/kg bwt) (F) | 67.1 ± 2.47 NS | 0.30 ± 0.02 NS | |||
| Two-way ANOVA | |||||
| Source of Variation | SS |
| MS |
|
|
| Between the groups (dosage) | 0.2129 | 3 | 0.07097 | 6.041 | .0005 |
| Within the groups (duration) | 4.887 | 416 | 0.01175 | ||
Abbreviations: ANOVA, analysis of variance; bwt, body weight; LPO-TBARS, lipid peroxidation thiobarbutiric acid reactive species; MDA, malonyldialdehyde; SE, standard error; SOD, superoxide dismutase; NS, nonsignificant analysis of variance at P < .05 significance level.
aValues are mean ± SE.
b P < .005.
c P < .001.
Figure 1.Alteration in lipid peroxidation (LPO) thiobarbutiric acid reactive species (TBARS) content in testis of control and treated animals.
Alteration in Oxidative Parameters GSH and GST Levels in Testis of Control and Treated Animals.a
| Groups | GSH (µg/100 mg tissue wt) | GST (units/mg protein) | |||
|---|---|---|---|---|---|
| Control (A) | 37.11 ± 0.63 | 0.297 ± 0.03 | |||
| Artesunate (150 mg/kg bwt) (B) | 27.20 ± 0.32b | 0.317 ± 0.05b | |||
| Artesunate (300 mg/kg bwt) (C) | 24.68 ± 0.63c | 0.360 ± 0.07c | |||
| Curcumin (80 mg/kg bwt) (D) | 42.50 ± 0.30 NS | 0.280 ± 0.04 NS | |||
| Artesunate (150 mg/kg bwt) + curcumin (80 mg/kg bwt) (E) | 31.91 ± 0.50 NS | 0.288 ± 0.01 NS | |||
| Artesunate (300 mg/kg bwt) + curcumin (80 mg/kg bwt) (F) | 28.62 ± 0.25 NS | 0.288 ± 0.03 NS | |||
| Two-way ANOVA Analysis | |||||
| Source of Variation | SS |
| MS |
|
|
| Between the groups (dosage) | 961.5 | 3 | 320.5 | 15.35 | .0001 |
| Within the groups (duration) | 8687 | 416 | 20.88 | ||
Abbreviations: ANOVA, analysis of variance; bwt, body weight; GSH, glutathione; GST, glutathione S transferase; NS, nonsignificant analysis of variance at P < .05 significance level; SE, standard deviation.
aValues are mean ± SE.
b P < .005.
c P < .001.
Figure 2.Alteration in superoxide dismutase (SOD) content in testis of control and treated animals.
Alteration in Oxidative Parameters G-Px and G-Rx Levels in Testis of Control and Treated Animals.a
| Groups | G-Px (GSH Consumed/mg Protein) | G-Rx (Moles NADPH Oxidized/min/mg Protein) | |||
|---|---|---|---|---|---|
| Control (A) | 11.98 ± 0.43 | 0.93 ± 0.14 | |||
| Artesunate (150 mg/kg bwt) (B) | 8.72 ± 0.43b | 0.69 ± 0.03b | |||
| Artesunate (300 mg/kg bwt) (C) | 7.90 ± 0.26c | 0.66 ± 0.04c | |||
| Curcumin (80 mg/kg bwt) (D) | 14.06 ± 0.27 NS | 1.17 ± 0.14 NS | |||
| Artesunate (150 mg/kg bwt) + curcumin (80 mg/kg bwt) (E) | 9.37 ± 0.27 NS | 0.74 ± 0.02 NS | |||
| Artesunate (300 mg/kg bwt) + curcumin (80 mg/kg bwt) (F) | 9.42 ± 0.25 NS | 0.71 ± 0.02 NS | |||
| Two-way ANOVA Analysis | |||||
| Source of Variation | SS |
| MS |
|
|
| Between the groups (dosage) | 90.64 | 3 | 30.21 | 11.08 | .0001 |
| Within the groups (duration) | 1134 | 416 | 2.726 | ||
Abbreviations: ANOVA, analysis of variance; bwt, body weight; G-Px, glutathione peroxidase; G-Rx, glutathione reductase; GSH, glutathione; GST, glutathione S transferase; NS, nonsignificant analysis of variance at P < .05 significance level; SE, standard deviation.
aValues are mean ± SE.
b P < .005.
c P < .001.
| Group | Group Name | Dosage | Duration |
|---|---|---|---|
| A | Control | – | 45 days |
| B | Low dose treated | 150 mg/kg bwt of artesunate | 45 days |
| C | High dose treated | 300 mg/kg bwt of artesunate | 45 days |
| D | Curcumin | 80 mg/kg bwt of curcumin | 45 days |
| E | Low dose + curcumin | 150 mg/kg bwt of artesunate + 80 mg/kg bwt of curcumin | 45 days |
| F | High dose + curcumin | 300 mg/kg bwt of artesunate + 80 mg/kg bwt of curcumin | 45 days |
Vehicle: distilled water. Number of animals in each group (n) = 6.